Van Geest, R. J., Lesnik-Oberstein, S. Y., Tan, H. S., Mura, M., Goldschmeding, R., Van Noorden, C. J. F., . . . Schlingemann, R. O. (2012). A shift in the balance of vascular endothelial growth factor and connective tissue growth factor by bevacizumab causes the angiofibrotic switch in proliferative diabetic retinopathy. BMJ Group.
Chicago Style CitationVan Geest, Rob J., Sarit Y. Lesnik-Oberstein, H Stevie Tan, Marco Mura, Roel Goldschmeding, Cornelis J F. Van Noorden, Ingeborg Klaassen, i Reinier O. Schlingemann. A Shift in the Balance of Vascular Endothelial Growth Factor and Connective Tissue Growth Factor By Bevacizumab Causes the Angiofibrotic Switch in Proliferative Diabetic Retinopathy. BMJ Group, 2012.
Cita MLAVan Geest, Rob J., et al. A Shift in the Balance of Vascular Endothelial Growth Factor and Connective Tissue Growth Factor By Bevacizumab Causes the Angiofibrotic Switch in Proliferative Diabetic Retinopathy. BMJ Group, 2012.